Document is current
Any future updates will be listed below
-
Authors
Brkic, Sime https://orcid.org/0000-0002-0148-6423
Stivala, Simona https://orcid.org/0000-0003-1549-8932
Santopolo, Alice
Szybinski, Jakub
Jungius, Sarah
Passweg, Jakob R.
Tsakiris, Dimitrios
Dirnhofer, Stefan
Hutter, Gregor
Leonards, Katharina https://orcid.org/0000-0002-4004-3473
Lischer, Heidi E. L. https://orcid.org/0000-0002-9616-2092
Dettmer, Matthias S. https://orcid.org/0000-0003-0948-1392
Neel, Benjamin G.
Levine, Ross L. https://orcid.org/0000-0002-7884-1905
Meyer, Sara C. https://orcid.org/0000-0002-0308-185X
- License Information
-
More Information
Article History
Received: 10 February 2021
Revised: 11 August 2021
Accepted: 18 August 2021
First Online: 3 September 2021
Competing interests
: SCM has consulted for and received honoraria from Celgene/BMS and Novartis. GH is co-founder and shareholder of Incephalo AG, received consulting honoraria from Novartis and B. Braun AG, and received research grants from Novartis Research Foundation. BGN is the co-founder of Northern Biologics, Ltd, Navire Pharmaceuticals, and Jengu Therapeutics and has an equity interest in each. He also receives consulting fees from the latter two companies. In addition, he is on the SAB of Arvinas, Inc., for which receives consulting fees and equity. His spouse holds shares in Amgen and during the course of this work also held shares in Arvinas, Moderna, and Regeneron. RLL is on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics and Isoplexis, which each include an equity interest. He receives research support from and consulted for Celgene and Roche, he has received research support from Prelude Therapeutics, and he has consulted for Incyte, Novartis, Morphosys and Janssen. He has received honoraria from Lilly and Amgen for invited lectures and from Gilead for grant reviews. All other authors do not have any competing interests.
